MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Climb Bio Inc. (NASDAQ: CLYM), formerly, Eliem Therapeutics, Inc. (NASDAQ: ELYM)*
Organization & Developments: Eliem
Parents
Climb Bio Inc. (NASDAQ: CLYM), formerly, Eliem Therapeutics, Inc. (NASDAQ: ELYM)*
Children
*Biotechnology company focused on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system.
2022: Announced that it did not meet its primary endpoint for its Phase 2a trial of ETX-810 in diabetic peripheral neuropathic pain.
2023: Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
2024: Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Jumps
*Key People: Eliem Therapeutics
Finance & Acquisitions: Eliem